Unbiased AI-powered news
Jenitar Na'amoana, 34, gave birth to four monozygotic girls by caesarean section on July 14 at Royal Brisbane and Women’s Hospital. The infants, born at 28 weeks and four days, share a single placenta and remain in neonatal intensive care.
The IndependentJenitar Na'amoana, 34, delivered four identical daughters by caesarean section at the Royal Brisbane and Women’s Hospital in Queensland on July 14. The infants were born at 28 weeks and four days gestation after a pregnancy that developed from a single fertilized egg splitting into four embryos sharing one placenta.
Na'amoana had been admitted to hospital at 25 weeks for monitoring, with doctors targeting 28 weeks.
Maternal foetal medicine specialist Dr Alexa Bendall, who oversaw the care, said the shared placenta raised the risk of mortality and morbidity for both mother and children. Bendall stated the odds of such a pregnancy stand at roughly one in 15 million. “This is unheard of.
We don’t think it has ever happened in Australia,” she said. “There may have been a couple of cases elsewhere in the world. ” The babies, named Emily, Harriet, Catherine and Alexa, remain in the neonatal intensive care unit.
Hospital staff said they are doing extremely well and are expected to stay until they approach full term. One infant was named Alexa after Dr Bendall. Bendall described the outcome as “incredible” and noted that Na'amoana avoided many of the major complications associated with multiple births.
Na'amoana and her husband already had four children aged between one and ten years old. Na'amoana has launched a GoFundMe campaign that GB News reported had raised more than A$37,000 to cover costs including a 10- or 12-seat van, medical expenses, travel, living costs and baby equipment.
These outlets didn't split into competing frames — coverage was uniform.
BBC NewsNovo Nordisk filed suit Tuesday alleging Eli Lilly used outdated trial data in ads for Zepbound and Mounjaro. The complaint seeks an injunction and corrective advertising.
msnbc.comBiotech firms are pressing the White House to exclude treatments for rare diseases from two Medicare pilot programs that lower brand drug prices. The Rare Disease Company Coalition met last week with the Office of Management and Budget to discuss the request.
koreatimes.co.krSamsung Biologics announced an all-cash tender offer to acquire PolyPeptide Group for 1.46 billion Swiss francs. The deal values the target at 38 Swiss francs per share and would add peptide manufacturing sites across five countries.